Establishment Labs (NASDAQ:ESTA) Stock Price Expected to Rise, BTIG Research Analyst Says

Establishment Labs (NASDAQ:ESTA) had its price target boosted by investment analysts at BTIG Research from $88.00 to $90.00 in a research note issued on Thursday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 25.40% from the company’s current price.

Other analysts also recently issued research reports about the stock. Needham & Company LLC raised their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Stephens raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Canaccord Genuity Group raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $71.77 on Thursday. The firm has a 50-day moving average of $65.27 and a 200-day moving average of $66.59. The company has a market cap of $2.11 billion, a P/E ratio of -48.17 and a beta of 1.12. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs has a one year low of $33.30 and a one year high of $83.31.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Wednesday, May 6th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 202.78%. The business’s revenue for the quarter was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.70) EPS. Equities research analysts forecast that Establishment Labs will post -0.83 EPS for the current fiscal year.

Insider Transactions at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 330,000 shares of company stock worth $22,854,538 in the last three months. Company insiders own 9.99% of the company’s stock.

Hedge Funds Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares during the period. Brian Low Financial Group LLC boosted its position in Establishment Labs by 10.2% during the first quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock worth $261,000 after purchasing an additional 424 shares during the period. KBC Group NV bought a new position in Establishment Labs during the first quarter worth about $28,000. Handelsbanken Fonder AB boosted its position in Establishment Labs by 7.3% during the fourth quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $641,000 after purchasing an additional 600 shares during the period. Finally, Swiss National Bank boosted its position in Establishment Labs by 1.8% during the fourth quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after purchasing an additional 600 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.